Inhaled insulin

Best Practice and Research: Clinical Endocrinology and Metabolism

Volumn 21, Issue 4, 2007, Pages 555-571

  Arnolds, Sabine ^a   Heise, Tim ^a  

^a PROFIL Institut für Stoffwechselforschung   (Germany)

Author keywords

clinical trials; efficacy; inhaled insulin; safety

Indexed keywords

FLUTICASONE; GLUCOSE; HUMAN INSULIN; INSULIN; INSULIN DERIVATIVE; INSULIN GLARGINE; INSULIN LISPRO; INSULIN ZINC SUSPENSION; ISOPHANE INSULIN; METFORMIN; ORAL ANTIDIABETIC AGENT; RECOMBINANT HUMAN INSULIN; ROSIGLITAZONE; SALBUTAMOL; SULFONYLUREA DERIVATIVE;

ASTHMA; BEDTIME DOSAGE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; COUGHING; DIABETES MELLITUS; DIET RESTRICTION; DIET THERAPY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CAPSULE; DRUG CONTRAINDICATION; DRUG COST; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FORMULATION; DRUG METABOLISM; DRUG SAFETY; DRUG STABILITY; DRUG STORAGE; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY POWDER; EXERCISE; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INHALER; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; LUNG DISEASE; LUNG EDEMA; LUNG FUNCTION; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATIENT SATISFACTION; PHARMACODYNAMICS; POSTPRANDIAL STATE; REIMBURSEMENT; RESPIRATORY TRACT INFECTION; REVIEW; RISK BENEFIT ANALYSIS; SIDE EFFECT; SINGLE DRUG DOSE; SMOKING; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN;

ABSORPTION; ADMINISTRATION, INHALATION; ASTHMA; BLOOD GLUCOSE; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; HYPOGLYCEMIA; INSULIN; INSULIN ANTIBODIES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RESPIRATORY TRACT INFECTIONS;

EID: 36549074512     PISSN: 1521690X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.beem.2007.07.004     Document Type: Review

References (92)

1. The Diabetes Control and Complications Trial (DCCT) Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The New England Journal of Medicine 329 (1993) 977-986
2. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352 (1998) 837-853
3. Hogan P., Dall T., and Nikolov P. Economic costs of diabetes in the US in 2002. Diabetes Care 26 (2003) 917-932
4. Cowie C.C., Rust K.F., Byrd-Holt D.D., et al. Prevalence of diabetes and impaired fasting glucose in adults in the U.S. population: National Health and Nutrition Examination Survey 1999-2002. Diabetes Care 29 (2006) 1263-1268
5. McMahon G.T., and Arky R.A. Inhaled insulin for diabetes mellitus. The New England Journal of Medicine 356 (2007) 497-502
6. FDA News 27.01.2006, Available at http://www.fda.gov/bbs/topics/news/2006/NEW01304.html.
7. Summers K.H., Szeinbach S.L., and Lenox S.M. Preference for insulin delivery systems among current insulin users and nonusers. Clinical Therapeutics 26 (2004) 1498-1505
8. Hunt L.M., Valenzuela M.A., and Pugh J.A. NIDDM patients' fears and hopes about insulin therapy: the basis of patient reluctance. Diabetes Care 20 (1997) 292-298
9. Peyrot M., Rubin R.R., Lauritzen T., et al. Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study. Diabetes Care 28 (2005) 2673-2679
10. Zambanini A., Newson R.B., Maisey M., et al. Injection related anxiety in insulin-treated diabetes. Diabetes Research and Clinical Practice 46 (1999) 239-246
11. Zambanini A., and Feher M.D. Needle phobia in type 1 diabetes mellitus. Diabetic Medicine 14 (1997) 321-323
12. Zambanini A., McIntosh C.S., Mitchell C., et al. Psychological issues in diabetes. Lancet 354 (1999) 74
13. Mollema E.D., Snoek F.J., Heine R.J., et al. Phobia of self-injecting and self-testing in insulin-treated diabetes patients: opportunities for screening. Diabetes Medicine 18 (2001) 671-674
14. Gale E.A. Two cheers for inhaled insulin. Lancet 357 (2001) 324-325
15. Calvert M.J., McManus R.J., and Freemantle N. The management of people with type 2 diabetes with multiple oral hypoglycaemic agents or insulin in primary care: retrospective cohort study. Diabetic Medicine 24 Suppl 1 (2007) 43
16. American Diabetes Association. Standards of medical care in diabetes-2007. Diabetes Care 30 Suppl 1 (2007) S4-S41
17. Brown J.B., Nichols G.A., and Perry A. The burden of treatment failure in type 2 diabetes. Diabetes Care 27 (2004) 1535-1540
18. Heise T., and Heinemann L. Rapid and long-acting insulin analogues as an approach to improve insulin therapy: an evidence-based medicine assessment. Current Pharmaceutical Design 7 (2001) 1303-1325
19. Koro C.E., Bowlin S.J., Bourgeois N., et al. Glycemic control 1988 to 2000 among U.S. adults diagnosed with type 2 diabetes: a preliminary report. Diabetes Care 27 (2004) 17-20
20. Gänsslen M. Über Inhalation von insulin. Klinische Wochenschrift 4 (1925) 71
21. Saudek C.D. Future developments in insulin delivery systems. Diabetes Care 16 Suppl 3 (1993) 122-132
22. Sayani A.P., and Chien Y.W. Systemic delivery of peptides and proteins across absorptive mucosae. Critical Reviews in Therapeutic Drug Carrier Systems 13 (1996) 85-184
23. Patton J.S. Deep lung delivery of therapeutic proteins. Chemtech 27 (1997) 34-38
24. Patton J. Pulmonary delivery of insulin. Current Medical Research Opinion 22 Suppl 3 (2006) S5-S11
25. Wall D.A. Pulmonary absorption of peptides and proteins. Drug Delivery 2 (1995) 1-20
26. Patton J.S., Bukar J., and Nagarajan S. Inhaled insulin. Advanced Drug Delivery Reviews 35 (1999) 235-247
27. Byron P.R. Prediction of drug residence times in regions of the human respiratory tract following aerosol inhalation. Journal of Pharmaceutical Sciences 75 (1986) 433-438
28. Kapitza C., Heise T., Fishman R.S., et al. Impact of particle size and aerosolization time on the metabolic effect of an inhaled insulin aerosol. Diabetes Technology & Therapeutics 6 (2004) 119-127
29. Muchmore D.B., and Gates J.R. Inhaled insulin delivery - where are we now?. Diabetes, Obesity and Metabolism 8 (2006) 634-642
30. Wolff R.K. Safety of inhaled proteins for therapeutic use. Journal of Aerosol Medicine 11 (1998) 197-219
31. Patton J.S., Bukar J.G., and Eldon M.A. Clinical pharmacokinetics and pharmacodynamics of inhaled insulin. Clinical Pharmacokinetics 43 (2004) 781-801
32. ® SPC, March 2007. Pfizer Ltd, Kent, UK.
33. Rave K.M., Nosek L., de la Pena A., et al. Dose response of inhaled dry-powder insulin and dose equivalence to subcutaneous insulin lispro. Diabetes Care 28 (2005) 2400-2405
34. Valente A., Langer R., Stone H.A., et al. Recent advances in the development of an inhaled insulin product. BioDrugs 17 (2003) 9-17
35. Pfützner A., Mann A.E., and Steiner S.S. TechnosphereTM/insulin - a new approach for effective delivery of human insulin via the pulmonary route. Diabetes Technology & Therapeutics 4 (2002) 589-594
36. Hermansen K., Ronnemaa T., Petersen A.H., et al. Intensive therapy with inhaled insulin via the AERx insulin diabetes management system: a 12-week proof-of-concept trial in patients with type 2 diabetes. Diabetes Care 27 (2004) 162
37. Hausmann M., Dellweg S., Osborn C., et al. Inhaled insulin as adjunctive therapy in subjects with type 2 diabetes failing oral agents: a controlled proof-of-concept study. Diabetes, Obesity and Metabolism 8 (2006) 574-580
38. Heinemann L., Traut T., and Heise T. Time-action profile of inhaled insulin. Diabetic Medicine 14 (1997) 63-72
39. Rave K., Bott S., Heinemann L., et al. Time-action profile of inhaled insulin in comparison with subcutaneously injected insulin lispro and regular human insulin. Diabetes Care 28 (2005) 1077-1082
40. Heinemann L., Klappoth W., Rave K., et al. Intra-individual variability of the metabolic effect of inhaled insulin together with an absorption enhancer. Diabetes Care 23 (2000) 1343-1347
41. Gelfand R.A., Schwartz S.L., Horton M.L., et al. Pharmacological reproducibility of inhaled human insulin pre-meal dosing in patients with type 2 diabetes mellitus. Diabetes 47 Suppl 1 (1998) A99
42. Kapitza C., Hompesch M., Scharling B., et al. Intrasubject variability of inhaled insulin in type 1 diabetes: a comparison with subcutaneous insulin. Diabetes Technology & Therapeutics 6 (2004) 466-472
43. Perera A.D., Kapitza C., Nosek L., et al. Absorption and metabolic effect of inhaled insulin: intrapatient variability after inhalation via the Aerodose insulin inhaler in patients with type 2 diabetes. Diabetes Care 25 (2002) 2276-2281
44. Pfützner A., Heise T., Steiner S., et al. Inhaled technosphere/insulin shows a low variability in metabolic action in type 2 diabetic patients. Diabetes 49 Suppl 1 (2000) A121
45. Heinemann L., and Heise T. Current status of the development of inhaled insulin. British Journal of Diabetes and Vascular Disease 4 (2004) 295-301
46. Kim D., Mudaliar S., Chinnapongse S., et al. Dose-response relationships of inhaled insulin delivered via the Aerodose insulin inhaler and subcutaneously injected insulin in patients with type 2 diabetes. Diabetes Care 26 (2003) 2842-2847
47. Berger M., and Mühlhauser I. Diabetes care and patient-oriented outcomes. JAMA 12 281 (1999) 1676-1678
48. ® insulin diabetes system. Diabetes Technology & Therapeutics 4 (2002) 499-504
49. Garg S., Rosenstock J., Silverman B.L., et al. Efficacy and safety of preprandial human insulin inhalation powder versus injectable insulin in patients with type 1 diabetes. Diabetologia 49 (2006) 891-899
50. ® inhaled insulin on treatment satisfaction, glycemic control and quality of life. Diabetes 55 Suppl 1 (2006) A100
51. ®/insulin in patients with type 2 diabetes mellitus. Diabetes 55 Suppl 1 (2006) A102
52. Boss A.H., Evans S.H., Ren H., et al. Superior post prandial glucose control in patients with type 1 diabetes when using prandial technosphere insulin compared to NovoLog. Diabetologia 49 Suppl 1 (2006) 0181
53. Skyler J.S., Cefalu W.T., Kourides I.A., et al. Efficacy of inhaled human insulin in type 1 diabetes mellitus: a randomised proof-of-concept study. Lancet 357 (2001) 331-335
54. Cappelleri J.C., Cefalu W.T., Rosenstock J., et al. Treatment satisfaction in type 2 diabetes: a comparison between an inhaled insulin regimen and a subcutaneous insulin regimen. Clinical Therapeutics 24 (2002) 552-564
55. Weiss S.R., Cheng S.L., Kourides I.A., et al. Inhaled insulin provides improved glycemic control in patients with type 2 diabetes mellitus inadequately controlled with oral agents: a randomized controlled trial. Archives of Internal Medicine 163 19 (2003) 2277-2282
56. Skyler J.S., Weinstock R.S., Raskin P., et al. Use of inhaled insulin in a basal/bolus regimen in type 1 diabetic subjects: a 6-month, randomized, comparative trial. Diabetes Care 28 (2005) 1630-1635
57. DeFronzo R.A., Bergenstal R.M., Cefalu W.T., et al. Efficacy of inhaled insulin in patients with type 2 diabetes not controlled with diet and exercise: a 12-week, randomized, comparative trial. Diabetes Care 28 (2005) 1922-1928
58. Hollander P.A., Blonde L., Rowe R., et al. Efficacy and safety of inhaled insulin (Exubera) compared with subcutaneous insulin therapy in patients with type 2 diabetes: results of a 6-month, randomized, comparative trial. Diabetes Care 27 (2004) 2356-2362
59. Rosenstock J., Zinman B., Murphy L.J., et al. Inhaled insulin improves glycemic control when substituted for or added to oral combination therapy in type 2 diabetes: a randomized, controlled trial. Annals of Internal Medicine 143 (2005) 549-558
60. Quattrin T., Belanger A., Bohannon N.J.V., et al. Efficacy and safety of inhaled insulin (Exubera) compared with subcutaneous insulin therapy in patients with type 1 diabetes: results of a 6-month, randomized, comparative trial. Diabetes Care 27 (2004) 2622-2627
61. Barnett A.H., Dreyer M., Lange P., et al. An open, randomized, parallel-group study to compare the efficacy and safety profile of inhaled human insulin (Exubera) with Metformin as adjunctive therapy in patients with type 2 diabetes poorly controlled on a sulfonylurea. Diabetes Care 29 (2006) 1282-1287
62. Barnett A.H., Dreyer M., Lange P., et al. An open, randomized, parallel-group study to compare the efficacy and safety profile of inhaled human insulin (Exubera) with glibenclamide as adjunctive therapy in patients with type 2 diabetes poorly controlled on Metformin. Diabetes Care 29 (2006) 1818-1825
63. Advisory Committee Briefing Document: Exubera (insulin (rDNA origin) powder for oral inhalation). Available at http://www.fda.gov/ohrms/dockets/ac/05/briefing/2005-416B1_01_01-Pfizer-Exubera.pdf, accessed on 14 March 2007.
64. Skyler J.S., Jovanovic L., Klioze S., et al. Two-year safety and efficacy of inhaled human insulin (Exubera) in adult patients with type 1 diabetes. Diabetes Care 30 (2007) 579-585
65. Jendle J.H., and Karlberg B.E. Effects of intrapulmonary insulin in patients with non-insulin-dependent diabetes. Scandinavian Journal of Clinical and Laboratory Investigation 56 (1996) 555-561
66. Edgerton D.S., Neal D.W., Scott M., et al. Inhalation of insulin (Exubera) is associated with augmented disposal of portally infused glucose in dogs. Diabetes 54 (2005) 1164-1170
67. Edgerton D.S., Cherrington A.D., Williams P., et al. Inhalation of human insulin (Exubera) augments the efficiency of muscle glucose uptake in vivo. Diabetes 55 (2006) 3604-3610
68. Cefalu W.T. Inhaled insulin: a proof-of-concept study. Annals of Internal Medicine 134 (2001) 795
69. Ceglia L., Lau J., and Pittas A.G. Meta-analysis: efficacy and safety of inhaled insulin therapy in adults with diabetes mellitus. Annals of Internal Medicine 145 (2006) 665-675
70. Rosenstock J., Cappelleri J.C., Bolinder B., et al. Patient satisfaction and glycemic control after 1 year with inhaled insulin (Exubera) in patients with type 1 or type 2 diabetes. Diabetes Care 27 (2004) 1318-1323
71. Scherbaum W.A. Unlocking the opportunity of tight glycaemic control. Inhaled insulin: Clinical efficacy. Diabetes, Obesity and Metabolism 7 Suppl 1 (2005) S9-S13
72. Chan N.N., Baldeweg S., Tan T.M., et al. Inhaled insulin in type 1 diabetes. Lancet 2001 (1979) 357
73. Teeter J.G., and Riese R.J. Dissociation of lung function changes with humoral immunity during inhaled human insulin therapy. American Journal of Respiratory and Critical Care Medicine 173 (2006) 1194-1200
74. Fineberg S.E., Kawabata T., Finco-Kent D., et al. Antibody response to inhaled insulin in patients with type 1 or type 2 diabetes. The Journal of Clinical Endocrinology and Metabolism 90 (2005) 3287-3294
75. Heise T., Bott S., Tusek C., et al. The effect of insulin antibodies on the metabolic action of inhaled and subcutaneous insulin. A prospective randomized pharmacodynamic study. Diabetes 28 (2005) 2161-2169
76. Henry R.R., Mudaliar S.R.D., Howland W.C., et al. Inhaled insulin using the AERx insulin diabetes management system in healthy and asthmatic subjects. Diabetes Care 26 (2003) 764-769
77. ®) pharmacokinetics in patients with mild-to-moderate asthma. Diabetes 55 Suppl 1 (2006) A112
78. ® inhaled insulin in subjects with chronic obstructive pulmonary disease: pharmacokinetics, glucodynamics, safety, and tolerability. Diabetes Care 30 7 (2007) 1777-1782
79. McElduff A., Mather L.E., Kam P.C., et al. Influence of acute respiratory tract infection on the absorption of inhaled insulin using the AERx insulin diabetes amangement system. British Journal of Clinical Pharmacology 59 (2005) 546-551
80. ®) therapy: a retrospective pooled analysis of controlled phase 2 and 3 trials. Diabetologia 49 Suppl 1 (2006) 616
81. Nakano M., Gern J., Stone C., et al. Can the human insulin inhalation powder (HIIP) delivery system can be used during an upper respiratory infection (URI)? The effect of URI on the pharmacokinetics (PK) and glucodynamics (GD) of HIIP in healthy subjects. Diabetologia 49 Suppl 1 (2006) 617
82. Himmelmann A., Jendle J., Mellen A., et al. The impact of smoking on inhaled insulin. Diabetes Care 26 (2003) 677-682
83. Becker R.H.A., Sha S., Frick A.D., et al. The effect of smoking cessation and subsequent resumption on absorption of inhaled insulin. Diabetes Care 29 (2006) 277-282
84. Wise S., Chien J., Yeo K., et al. Smoking enhances absorption of insulin but reduces glucodynamic effects in individuals using the Lilly-Dura inhaled insulin system. Diabetic Medicine 23 (2006) 510-515
85. Nathan D.M. Counterpoint: no time to inhale: arguments against inhaled insulin in 2007. Diabetes Care 30 (2007) 442-443
86. Von Kriegstein E., and von Kriegstein K. Inhaled insulin for diabetes mellitus. The New England Journal of Medicine 356 (2007) 2106
87. National Institute for Health and Clinical Excellence. Inhaled insulin for the treatment of diabetes (types 1 and 2). Available at (December 2006). http://www.nice.org/TA113 accessed on 14 March 2007
88. Cook M.N., Girman C.J., Stein P.P., et al. Glycemic control continues to deteriorate after sulfonylureas are added to metformin among patients with type 2 diabetes. Diabetes Care 28 (2005) 995-1000
89. Freemantle N., Blonde L., Duhot D., et al. Availability of inhaled insulin promotes greater perceived acceptance of insulin therapy in patients with type 2 diabetes. Diabetes Care 28 (2005) 427-428
90. ®) improve management of type 2 diabetes? The design of the real world trial. Trials 7 (2006) 25
91. Liebl A., Neiss A., Apannheimer A., et al. Kosten des Typ-2 Diabetes in Deutschland. Ergebnisse der Code-2 Studie. Deutsche medizinische Wochenschrift 126 (2001) 585-589
92. Baxter Press Release, Available at http://www.baxter.com/about_baxter/news_room/news_releases/2007/04-20-07-promaxx.html